Eli Lilly (LLY) Return on Invested Capital (2009 - 2026)
Eli Lilly (LLY) reported Return on Invested Capital of 0.0% for Q1 2026, down 1.0% on a YoY basis from 0.0% in Q1 2025, and up 8.59% quarter-over-quarter from 0.0% in Q4 2025.
Eli Lilly (LLY) Return on Invested Capital (2009 - 2026) Analysis & Trends
Eli Lilly has reported Return on Invested Capital for 18 years, with the latest figure at 0.0% in Q1 2026.
- For the quarter ending Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (down 1.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
- The five-year high for Return on Invested Capital was 0.09% in Q2 2025, with the low at 0.0% in Q4 2025.
- Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.01% in 2023.
- The largest YoY upside for Return on Invested Capital was 8 bps in 2025 against a maximum downside of 1 bps in 2025.
- Eli Lilly's Return on Invested Capital stood at 0.01% in 2022, then soared by 56 bps to 0.01% in 2023, then climbed by 7 bps to 0.01% in 2024, then slumped by 68 bps to 0.0% in 2025, then grew by 9 bps to 0.0% in 2026.
- The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 0.00% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.00% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.00% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 0.00% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 0.00% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.00% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.00% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 0.00% |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.01% |
| Jun 30, 2025 | 0.09% |
| Mar 31, 2025 | 0.01% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | 0.01% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 0.02% |
| Dec 31, 2023 | 0.01% |
| Sep 30, 2023 | 0.01% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.01% |
| Sep 30, 2022 | 0.01% |
| Jun 30, 2022 | 0.01% |
| Mar 31, 2022 | 0.01% |
| Dec 31, 2021 | 0.01% |
| Sep 30, 2021 | 0.01% |
| Jun 30, 2021 | 0.01% |